The US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly 13bn (£9.8bn) in global sales from their coronavirus vaccine next year, which will be evenly split between the two companies, according to analysts at the US investment bank Morgan Stanley.
Pfizer’s half would be more than the US pharmaceutical group’s bestselling product, a pneumonia vaccine that generated 5.8bn last year.